Articles related to TRANSPLANT MEDICINE

“Although historically grouped together, viral-associated PCNSL subtypes are biologically distinct diseases. Each escapes immune control through a different mechanism, creating fundamentally different tumor microenvironments.” – Melinda Burgess, Researcher from the Department of Haematology at Princess Alexandra Hospital

Similar efficacy was observed in pediatric patients aged 12 years and older – demonstrating consistent treatment benefit across age groups in the pivotal trial.

“Mean LOS post-transplant was significantly shorter in the post-APP cohort (P = .005). The mean LOS for the pre- and post-APP cohorts were 22.4 and 16.5 days, respectively.”

Posttreatment dosimetric analysis demonstrated that higher specific activity microspheres overcome tumor heterogeneity by ensuring adequate radiation delivery throughout the entire tumor volume, particularly in poorly perfused regions.

The procedure addresses limitations of current intestinal reconstruction methods, potentially eliminating associated bleeding risks, infections, and digestive complications while providing more physiologically normal urinary function.

The phase 3 ALLELE trial demonstrated tabelecleucel’s potential with a 50.7% overall response rate and median duration of response of 23.0 months in EBV+ PTLD patients.